Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Hideaki Shiraishi, Yutaka Fujiwara, Takanori Kakuya, Koji Tsuta, Noriko Motoi, Nami Miura, Yukio Watabe, Shun Ichi Watanabe, Rintaro Noro, Kengo Nagashima, Wilber Huang, Tesshi Yamada, Hisao Asamura, Yuichiro Ohe, Kazufumi Honda

研究成果: Article査読

9 被引用数 (Scopus)

抄録

Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

本文言語English
ページ(範囲)721-731
ページ数11
ジャーナルBiomarkers in Medicine
11
9
DOI
出版ステータスPublished - 2017 9月

ASJC Scopus subject areas

  • 創薬
  • 臨床生化学
  • 生化学、医学

フィンガープリント

「Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル